Tslpr-cart

Phase 1

NNational Cancer Institute (NCI)

Tslpr-cart is one of 3 therapeutic programs targeting B-ALL. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

B-ALLNot yet recruiting

B-ALLPhase 1

Not yet recruiting

Competition

Competitive Landscape

2 competitors in B-ALL

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 1

1 2

Cytoxan

BBaxter Healthcare Corporation

Phase 1

1 3

Tslpr-cart

NNational Cancer Institute (NCI)

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2032

Phase 1Not yet recruiting

B-ALL

NCT07572136

Clinical

Trials by Indication[1]

B-ALL1 trial

Phase I Dose Escalation Study of Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-cell Acute Lymphoblastic Leukemia (B-ALL)

Not yet recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT07572136·57 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tslpr-cart. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Tslpr-cart. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: NNational Cancer Institute (NCI)

Tslpr-cart

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2032

Trials by Indication[1]

B-ALL1 trial

References

Drug Info

Quick Facts

Related News